Therapeutic potential of plasma gelsolin administration in a rat model of sepsis

Cytokine

Volumn 54, Issue 3, 2011, Pages 235-238

  Cohen, Taylor S ^a   Bucki, Robert ^b   Byfield, Fitzroy J ^b   Ciccarelli, Nicholas J ^b   Rosenberg, Brenna ^a   DiNubile, Mark J ^c   Janmey, Paul A ^b   Margulies, Susan S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Gelsolin; Sepsis; Tissue injury

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; CILIARY NEUROTROPHIC FACTOR; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT 2; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT 3; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FRACTALKINE; GAMMA INTERFERON; GELSOLIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1A; INTERLEUKIN 1B; INTERLEUKIN 4; INTERLEUKIN 6; LACTATE DEHYDROGENASE; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR BETA SUBUNIT; SODIUM CHLORIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; ENZYME ACTIVITY; INTESTINE SURGERY; MALE; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEPSIS; TISSUE INJURY;

ALANINE TRANSAMINASE; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; GELSOLIN; HUMANS; INFLAMMATION; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; L-LACTATE DEHYDROGENASE; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS;

ANIMALIA; RATTUS;

EID: 79955156157     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.02.006     Document Type: Article

References (11)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
2. Riedemann N.C., Guo R.F., Ward P.A. The enigma of sepsis. J Clin Invest 2003, 112:460-467.
3. Wen D., Corina K., Chow E.P., et al. The plasma and cytoplasmic forms of human gelsolin differ in disulfide structure. Biochemistry 1996, 35:9700-9709.
4. Lee P.S., Waxman A.B., Cotich K.L., et al. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med 2007, 35:849-855.
5. Bucki R., Levental I., Kulakowska A., et al. Plasma gelsolin: function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci 2008, 9:541-551.
6. Wang H., Cheng B., Chen Q., et al. Time course of plasma gelsolin concentrations during severe sepsis in critically ill surgical patients. Crit Care 2008, 12:R106.
7. Rothenbach P.A., Dahl B., Schwartz J.J., et al. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol 2004, 96:25-31.
8. Christofidou-Solomidou M., Scherpereel A., Solomides C.C., et al. Changes in plasma gelsolin concentration during acute oxidant lung injury in mice. Lung 2002, 180:91-104.
9. Levine G.K., Deutschman C.S., Helfaer M.A., et al. Sepsis-induced lung injury in rats increases alveolar epithelial vulnerability to stretch. Crit Care Med 2006, 34:1746-1751.
10. Lee P.S., Patel S.R., Christiani D.C., et al. Plasma gelsolin depletion, circulating actin in sepsis: a pilot study. PLoS ONE 2008, 3:e3712.
11. Frink M., van Griensven M., Kobbe P., et al. IL-6 predicts organ dysfunction, mortality in patients with multiple injuries. Scand J Trauma Resusc Emerg Med 2009, 17:49.